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Background: Although the understanding of the genetic and molecular basis of cancer has advanced significantly
over the past several decades, imaging and treatment options for glioblastoma patients have been more limited
(N Engl J Med 359:492-507, 2008). This is in part due to difficulties in diagnosing this disease early, combined with
its diffuse, infiltrative growth. This study was aimed at the development of a novel diagnostic tool for glioblastoma
through the synthesis of a small molecule based on radioiodinated poly(ADP-ribose)polymerase 1 (PARP1) targeted
tracers. This PARP1 is a biomarker that is overexpressed in glioblastoma tissue, but has only low expression levels in
the healthy brain (Neoplasia 16:432-40, 2014).
Methods: A library of PARP1 inhibitors (iodo-PARPis) was synthesized. Based on their pharmacokinetic properties
and nuclear PARP1 binding, the most successful inhibitor was radiolabeled with 131I and 124I. Biodistribution as well
as imaging experiments were performed in orthotopic and subcutaneous mouse models of glioblastoma.
Results: One member of our iodo-poly(ADP-ribose)polymerase 1 (PARP1) inhibitor library, I2-PARPi, shows promising
biophysical properties for in vivo application. All synthesized tracers have IC50 values in the nanomolar range
(9 ± 2–107 ± 4 nM) and were able to inhibit the uptake of a fluorescent PARP1 inhibitor analog (PARPi-FL).
I2-PARPi was able to reduce the uptake of PARPi-FL by 78 ± 4 % in vivo. In mouse models of glioblastoma, we
show that the radioiodinated inhibitor analog has high uptake in tumor tissue (U251 MG xenograft, tumor,
0.43 ± 0.06 %ID/g; brain, 0.01 ± 0.00 %ID/g; muscle, 0.03 ± 0.01 %ID/g; liver, 2.35 ± 0.57 %ID/g; thyroid, 0.24 ± 0.06 %ID/g).
PET and SPECT imaging performed in orthotopic glioblastoma models with [124I]- and [131I]-I2-PARPi showed selective
accumulation in the tumor tissue. These results were also verified using autoradiography of tumor sections, which
displayed focal selective uptake of the tracer in the tumor regions as confirmed by histology. The uptake could be
blocked through pre-injection of excess unlabeled PARP1 inhibitor (Olaparib).
Conclusions: We have successfully synthesized and radioiodinated the PARP1 selective tracer I2-PARPi. The novel tracer
shows selective binding to tumor tissue, both in vitro and in models of glioblastoma, and has the potential to serve as a
selective PET imaging agent for brain tumors.
Keywords: PARP1; Glioblastoma; 131I; 124I; PET; SPECT; U87 MG; U251 MG* Correspondence: reinert@mskcc.org
1Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275
York Avenue, New York, NY 10065, USA
3Weill Cornell Medical College, New York, NY 10065, USA
Full list of author information is available at the end of the article
© 2015 Salinas et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Salinas et al. EJNMMI Research  (2015) 5:46 Page 2 of 14Background
State-of-the-art cancer care is stricken by our inability
to efficiently treat, inhibit, and ultimately cure tumor
growth for the vast majority of primary cancers. And
while for most types of cancer, the diagnosis and detection
of lesions has seen significant improvements over the past
decades [3], some are often detected at late stages, when
therapeutic options are limited. Therefore, early detection
remains an unmet clinical need. This is also the case for
glioblastoma, the most common cancer in the adult brain.
Malignant gliomas are diffusely infiltrative, which limits
the use of current diagnostic tools, typically MRI, to detect
small pockets of tumor cells, which have invaded the
healthy brain [1, 4–7]. Therefore, better and more specific
glioblastoma imaging agents with higher signal/noise
ratios are needed, which would enable more accurate
detection and delineation of infiltrative tumor regions,
ultimately leading to better resection and surgical out-
comes [7, 8]. Our previous work has shown that small
molecular PARP1 inhibitors, like the fluorescent PARPi-FL,
accumulate in the nucleus of glioblastoma cells at high
concentrations and with high specificity [2]. PARP1 is a
near-ideal imaging target for glioblastoma. It holds a
unique role in maintaining the integrity of the genome,
and the enzyme is one of the key players responsible for
DNA repair [7, 9–11]. As a cellular response to DNA dam-
age, PARP1 is activated [12–15]. Due to rapid proliferation,
genetic instability, and metabolic stress, DNA damage is
more likely to happen in cancer cells than healthy tissue
[11]. As a result, PARP1 is highly overexpressed in various
forms of cancer [16–21]. This is particularly apparent in
mouse models of glioblastoma, where tumor tissue is
overexpressing PARP1, whereas healthy brain tissue has
very low levels of the enzyme. This drastic difference in
expression levels was also observed in human tissue
[19] and led us to believe that a non-invasive imaging
agent for PARP1 could be used to detect glioblastoma
with high signal/noise ratios.
The goal of this project was therefore to develop a
non-invasive PET-based imaging platform for PARP1.
Based on our successful optical PARP1 imaging agents,
we chose a 2H-phthalazin-1-one scaffold [22] previously
used by us for targeting glioblastoma cells [23]. We de-
scribe the synthesis of a targeted PARP1 tracer, which
was labeled with the radioisotopes 131I and 124I (for
SPECT and PET imaging, respectively). Specifically, we
show the design of small molecular targeted agents and
their validation in biochemical assays, both in cells and
in vivo. We further use one tracer for 131I/124I SPECT
and PET imaging of PARP1 in subcutaneous and ortho-
topic mouse models of cancer, thereby illustrating that
the expression of PARP1 is highly upregulated and that
our labeled tracer accumulates inside the nuclei of glio-
blastoma cells, where PARP1 is expressed.Methods
Unless otherwise noted, all reagents were purchased from
Sigma-Aldrich (St. Louis, MO) and used without further
purification. N-succinimidyl-4-(tributylstannyl) benzoate
was purchased from Synthonix (Cambridge, UK), 3-(3-
iodophenyl)propionic acid and 3-(4-iodophenyl)propionic
acid from Matrix Scientific (Columbia, SC), and 4-
iodophenyl acetic acid from Alfa Aesar (Cambridge,
UK). Olaparib (AZD2281) was purchased from LC La-
boratories (Woburn, MA). 4-(4-Fluoro-3-(piperazine-1-
carbonyl)benzyl)phthalazin-1(2H)-one was synthesized
as described previously [22]. 1H-nuclear MR (NMR) spec-
tra were recorded at room temperature on a Bruker
Avance 500 instrument operating at the frequency of
500 MHz (Billerica, MA) and internally referenced to the
residual solvent peaks, CDCl3 (7.26 ppm) or dimethyl sulf-
oxide (DMSO)-d6 (2.49 ppm). Mass spectroscopy data
was recorded on a Waters Acquity Ultra Performance LC
(Milford, MA). High-resolution mass data was recorded
on a Waters LCT Premier XE mass spectrometer. High-
performance liquid chromatography (HPLC) and radio-
HPLC was performed on a Shimadzu HPLC system
equipped with 2LC-10AT pumps and an SPD-M10AVP
photodiode array detector (Columbia, MD). Radio-HPLC
was performed using an identical Shimadzu system,
additionally equipped with a Lablogic Scan-RAM Radio-
TLC/HPLC detector (Brandon, FL). Analytic runs were
performed on a C18 Waters Atlantis T3 column (6 ×
250 mm, 5 mm). The solvent system included water
(solvent A) and acetonitrile (AcN) (solvent B) for the
purification and quality control of the radiotracers with
a gradient of 5–95 % B between 0 and 15 min and
100 % B between 15 and 25 min. For the purification of
non-radioactive precursors, water (0.1 % trifluoroacetic
acid, solvent A) and acetonitrile (AcN) (0.1 % trifluor-
oacetic acid, solvent B) were used, all with a flow rate
of 1 mL/min and a gradient of 5–95 % B between 0 and
15 min, 95 % B between 15 and 17 min, and 95–5 % B
between 17 and 18 min.
Synthesis of PARP1 inhibitors
4-(4-fluoro-3-(4-(3-iodobenzoyl)piperazine-1-
carbonyl)benzyl)phthalazin-1(2H)-one (I1-PARPi)
To a solution of 4-(4-Fluoro-3-(piperazine-1-carbonyl)ben-
zyl)phthalazin-1(2H)-one (10 mg, 0.0275 mmol), triethyla-
mine (40 μL, 0.3 mmol) and HBTU (16 mg, 0.0413 mmol)
in dimethyl formamide (DMF, 500 μL) were added to 3-
iodobenzoic acid (6 mg, 0.0275 mmol). The mixture was
stirred at room temperature for 20 h. The crude product
was then purified by preparative HPLC and dried under
vacuum, yielding a white solid (6.9 mg, 48 % yield).
1H-NMR (CDCl3) δ = 10.00 (s, 1H), 8.40–8.38 (m, 1H),
7.71–7.69 (m, 4H), 7.64–7.63 (m, 1H), 7.30–7.26 (m,
3H), 7.09 (m, 1H), 7.04–6.87 (m, 1H), 4.21 (s, 2H),
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A solution of 4-(4-fluoro-3-(piperazine-1-carbonyl)ben-
zyl)phthalazin-1(2H)-one (10 mg, 0.0275 mmol), HBTU
(16 mg, 0.0413 mmol), triethylamine (40 μL, 0.3 mmol),
and 4-iodobenzoic acid (6 mg, 0.0245 mmol) in DMF
(500 μL) was stirred overnight at room temperature. The
crude product was purified by preparative HPLC and
dried under vacuum, yielding a white solid (8.8 mg,
61 % yield). 1H-NMR (CDCl3) δ = 10.48 (s, 1H), 8.40–
8.39 (m, 1H), 7.74–7.66 (m, 5H), 7.27–7.26 (d, 2H), 7.09–
7.07 (d, 2H), 4.22 (s, 2H), 3.73–3.14 (m, 8H). LC-ESI-MS
(+) m/z = 597.1 [M+H+]+. HRMS-ESI [M-H+]− m/z calcu-
lated for [C27H22FIN4O3]
− 595.0642, found 595.0640.
4-(4-fluoro-3-(4-(2-(3-iodophenyl)acetyl)piperazine-1-
carbonyl)benzyl)phthalazin-1(2H)-one (I3-PARPi)
A solution of 3-iodophenyl acetic acid (6.5 mg,
0.048 mmol), 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide (EDC) (10.5 mg, 0.055 mmol), N-hydroxy succini-
mide (NHS), and 600 μL DMF was stirred for 30 min at
room temperature. Then, 4-(4-fluoro-3-(piperazine-1-car-
bonyl)benzyl)phthalazin-1(2H)-one (10 mg, 0.0275 mmol)
was added to the solution, and the mixture was stirred
at room temperature overnight. The reaction was
washed with 500 μL of H2O and extracted with 500 μL
dichloromethane (DCM). The resulting organic solu-
tion was purified on silica gel, using a gradient elution
from neat DCM to DCM/hexane 5:1 to obtain the
desired product as a white solid (3 mg, 20 % yield).
1H-NMR (CDCl3) δ = 9,82 (s, 1H), 8.40–8.38 (m, 1H),
7.71–7.69 (m, 2H), 7.55–7.53 (m, 1H), 7.51–7.50 (m, 2H),
7.25–7.24 (m, 2H), 7.09–6.90 (m, 3H), 4.20 (s, 2H),
3.64–3.31 (m, 8H), 2.84 (s, 2H). LC-ESI-MS (+) m/z =
633.1 [M+Na+]+. HRMS-ESI [M+H+]+ m/z calculated for
[C28H24FIN4O3]
+ 611.0955, found 611.0948.
4-(4-fluoro-3-(4-(2-(4-iodophenyl)acetyl)piperazine-1-
carbonyl)benzyl)phthalazin-1(2H)-one (I4-PARPi)
A solution of 4-iodophenyl acetic acid (6.5 mg,
0.048 mmol), EDC (10.5 mg, 0.055 mmol), NHS, and
600 μL DMF was stirred for 30 min at room temperature.
After this time, the 4-(4-fluoro-3-(piperazine-1-carbonyl)-
benzyl)phthalazin-1(2H)-one (10 mg, 0.0275 mmol) was
added to the solution and the mixture was stirred at room
temperature overnight. H2O (500 μL) was added, the mix-
ture was extracted with DCM (2 × 500 μL), and the com-
bined extracts were dried under vacuum. The crude
mixture was purified by silica column chromatography
(100 % DCM), and the product obtained was a whitesolid (8.8 mg, 61 %). 1H-NMR (CDCl3) δ = 9.82 (s, 1H),
8.40–8.38 (m, 1H), 7.83–7.81 (d, 1H), 7.77–7.75 (d, 1H),
7.70–7.69 (m, 2H), 7.63–7.56 (m, 3H), 7.00–6.89 (m, 3H),
4.20 (s, 2H), 3.63–3.11 (m, 8H), 2.84 (s, 2H). LC-ESI-MS
(+) m/z = 632.9 [M+Na+]+. HRMS-ESI [M+H+]+ m/z calcu-
lated for [C28H24FIN4O3]
+ 611.0955, found 611.0971.
4-(4-fluoro-3-(4-(3-(3-iodophenyl)propanoyl)piperazine-1-
carbonyl)benzyl)phthalazin-1(2H)-one (I5-PARPi)
A solution of 4-(4-fluoro-3-(piperazine-1-carbonyl)ben-
zyl)phthalazin-1(2H)-one (10 mg, 0.0275 mmol), HBTU
(16 mg, 0.0413 mmol), triethylamine (40 μL, 0.3 mmol),
and 3-(3-iodophenyl)propionic acid (7.6 mg, 0.0275 mmol)
in 400 μL of AcN was stirred overnight at room
temperature. The crude product was then purified by pre-
parative HPLC and the isolated product dried at vacuum
to obtain a white solid (5.1 mg, 38 %). 1H-NMR (CDCl3)
δ = 10.33 (s, 1H), 8.41–8.39 (d, 1H), 7.71–7.63 (m, 3H),
7.51–7.45 (m, 2H), 7.27–7.25 (m, 2H), 7.12–6.92 (m, 3H),
4.22 (s, 2H), 3.65–3.12 (m, 8H), 2.88–2.83 (m, 2H), 2.59–
2.48 (m, 2H). LC-ESI-MS (+) m/z = 647.1 [M+Na+]+.






1(2H)-one (10 mg, 0.0275 mmol) was mixed with
HBTU (16 mg, 0.0413 mmol), triethylamine (40 μL,
0.3 mmol), and 4-iodo-3-phenyl propionic acid (7.6 mg,
0.0275 mmol) in 400 μL of AcN, and the solution was
stirred overnight at room temperature. The crude product
was then purified by preparative HPLC and the isolated
product dried at vacuum to obtain a white solid (7.5 mg,
45 %). 1H-NMR (CDCl3) δ = 9.71 (s, 1H), 8.40–8.38 (d,
1H), 7.70–7.69 (m, 2H), 7.64–7.63 (m, 1H), 7.55–7.52
(m, 2H), 7.27–7.25 (m, 2H), 7.00–6.97 (m, 1H), 6.91–
6.87 (m, 2H), 4.20 (s, 2H), 3.64–3.11 (m, 8H), 2.87–2.85
(m, 2H), 2.63–2.47 (m, 2H). LC-ESI-MS (+) m/z =
647.1 [M+Na+]+. HRMS-ESI [M+Na+]+ m/z calculated
for [C29H26FIN4O3Na]
+ 647.0931, found 647.0941.
Radiochemistry
[131I]-NaI was purchased at Nordion (Ottawa, ON,
Canada) in NaOH solution (0.1 M) with a concentration
of 0.99–2.5 mCi/μL. [124I]-NaI was produced at Memorial
Sloan-Kettering Cancer Center (New York, NY) in NaOH
solution (0.5 M) with a concentration of 0.20–0.40 mCi/μL.
Synthesis of [131I]-NHS-benzoate
Precursor N-succinimidyl-4-(tributylstannyl) benzoate
(30 μg, 5.9 nmol) was dissolved in 30 μL of AcN, and
the solution was added to a solution of methanol
(40 μL), chloramine T (6 μg, 0.03 nmol) in acetic acid
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5 min at room temperature, the reaction was purified by
HLPC on a C18 Waters Atlantis T3 column (6 ×
250 mm, 5 mm), using water (solvent A) and AcN (solv-
ent B) as mobile phase, with an elution gradient from 5
to 100 % for solvent B over 15 min and then 100 % of
solvent B from 15 to 25 min. The retention time of [131I]-
NHS benzoate was 14.3 min, and its identity was estab-
lished by co-elution with the reference cold compound.
The radiochemical yield was 67 ± 6 % (n = 12), and the
radiochemical purity was >98 %. The collected fraction
containing [131I]-NHS benzoate was concentrated to dry-
ness under vacuum.
The same procedure was followed for the synthesis of
[124I]-NHS benzoate. In this case, the radiochemical
yield was 32 ± 5 % (n = 5) and the purity was >95 %.
Synthesis of [131I]-I2-PARPi
The dried radiolabeled [131I]-NHS-benzoate precursor
was dissolved in 200 μL of AcN, and an excess of HBTU
(1 mg, 2.6 nmol) and 4-(4-fluoro-3-(piperazine-1-carbo-
nyl)benzyl)phthalazin-1(2H)-one (1 mg, 2.7 nmol) was
added and allowed to react for 3 h at 32 °C. The final
product was purified by HPLC, using water (solvent A)
and AcN (solvent B) as solvents with a gradient elution
from 5 to 100 % of solvent B over 15 min and then
100 % of B from 15 to 25 min. The retention time of
[131I]-I2-PARPi was 13.1 min, and its identity was estab-
lished by co-elution with the reference cold compound.
The radiochemical yield was 72 ± 8 % (n = 12) and the
radiochemical purity >95 %. The collected fraction con-
taining [131I]-I2-PARPi was concentrated to dryness
under reduced pressure.
The same procedure was followed for the synthesis of
[124I]-I2-PARPi. In this case, the radiochemical yield was
68 ± 5 % (n = 5) and the purity >95 %.
Cell culture
The human glioblastoma cell lines U251 MG and U87
MG were generously provided by the Laboratory of Dr.
Ronald Blasberg (MSKCC, New York, NY). All cell lines
were grown in Eagle’s minimal essential medium (MEM)
containing 10 % (v/v) heat-inactivated fetal bovine
serum, 100 IU penicillin, and 100 μg/mL streptomycin.
Cells were cultured at 37 °C in a humidified 5 % CO2
atmosphere. All media was purchased from the media
preparation facility at MSKCC (New York, NY).
Mouse models
Six 10-week-old female athymic nude CrTac:NCr-Fo
mice from Taconic Laboratories (Hudson, NY) were
used for all mouse experiments. During subcutaneous
injections, mice were anesthetized using 2 % isoflurane
gas in 2 L/min medical air. During orthotopic injections,mice were anesthetized using a 150 mg/kg ketamine and
15 mg/kg xylazine cocktail (10 μL/g). Before all intraven-
ous injections, mice were gently warmed with a heat
lamp and placed in a restrainer and tails were sterilized
with alcohol pads. The lateral tail vein was used for all
intravenous injections. All mouse experiments were
done in accordance with protocols approved by the
Institutional Animal Care and Use Committee of MSKCC
and followed National Institutes of Health (NIH) guide-
lines for animal welfare.
PARP-1 IC50 determination
A commercially available colorimetric assay (Trevigen,
Gaithersburg, MD) was used to measure PARP-1 activity
in vitro in the presence of varying concentrations of the
different iodo-PARPis. Specifically, dilutions of iodo-
PARPi (final concentrations ranging from 3.3 μM to 0.1
nM) were incubated with 0.5 U of PARP1 high specific
activity (HSA) enzyme for 10 min in histone-coated 96-
well plates. All experiments were carried out in tripli-
cate. Positive control samples did not contain inhibitor,
and negative control samples did not contain PARP1. All
reaction mixtures were adjusted to a final volume of
50 μl, and a final concentration of 1 % DMSO in assay
buffer. The remainder of the assay was performed accord-
ing to the manufacturer’s instructions. PARP1 activity was
measured by absorbance at 450 nm in each well using a
SpectraMax M5 spectrophotometer with SoftMax Pro
software (Molecular Devices, Sunnyvale, CA).
Hydrophobicity index determination
Chemical hydrophobicity indices (CHIs) were measured
using procedures developed previously [24]. Briefly, re-
verse phase HPLC was used to measure the retention
times of a set of standards with known CHI. A standard
curve was then created to calculate the CHIs of all iodo-
PARPi based on the HPLC retention time. Log P values
were derived from CHI values following the equation:
Log P = 0.0566 ± CHI − 1.107.
Plasma protein fraction
The plasma protein fraction was determined using the
Rapid Equilibrium Dialysis Device System (Life Tech-
nologies, Grand Island, NY) according to the manufac-
turer’s protocol. Membrane dialysis was performed with
10 μM of compound in mouse serum (500 μL) on one
side of the membrane and PBS (750 μL) on the other
side. The system was sealed with parafilm and incubated
for 4 h at 37 °C on an orbital shaker set to 250 rpm.
Thereafter, 400 μL of solution was taken from both
sides, and samples were treated twice with an equal
amount of AcN and vortexed to remove protein before
HPLC analysis. After injection (100 μL), the I-PARPi
peaks from each sample were then integrated and the
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Immunohistochemistry
PARP1 expression in tissues
PARP1 antigen detection in glioblastoma xenografts and
mouse brain was performed at MSKCC’s Molecular
Cytology Core Facility using the Discovery XT processor
(Ventana Medical Systems, Tucson, AZ) and detected using
immunofluorescence (IF) staining. Paraffin-embedded
formalin-fixed 3 μm sections were deparaffinized with
EZPrep buffer, antigen retrieval was performed with
CC1 buffer (both Ventana Medical Systems), and sec-
tions were blocked for 30 min with Background Buster
solution (Innovex, Richmond, CA). Anti-PARP1 rabbit
polyclonal antibody (sc-7150, 0.2 μg/mL; Santa Cruz
Biotechnology, Santa, Cruz, CA) was incubated for 5 h,
followed by 1 h incubation with biotinylated goat anti-
rabbit IgG (Vector labs, PK6106) at a 1:200 dilution.
Detection was performed with Streptavidin-HRP D
(from DABMap Kit, Ventana Medical Systems), followed
by incubation with Tyramide Alexa Fluor 594 (T20935;
Invitrogen, Carlsbad, CA) prepared according to the manu-
facturer’s instructions. Sections were counterstained with
4′,6-diamidino-2-phenylindole (DAPI) and coverslipped
with Mowiol® mounting medium (Sigma-Aldrich, St. Louis,
MO). H&E staining was performed on adjacent sections
for morphological evaluation of tissue characteristics.
Quantification of PARP1 expression
Protein expression was quantified on digitalized PARP1-
stained sections using at least ten fields of view per
section. Thresholding of the blue (nuclei stained with
DAPI) and red fluorescent area (nuclei stained with
PARP1) was performed using MetaMorph® Software
(Molecular Devices, Sunnyvale, CA). PARP1 intensity was
determined by measuring the red fluorescence intensity in
the area of all nuclei, and the % PARP1 positive nuclear
area was calculated by dividing the PARP1 positive area by
the DAPI positive area in each field of view.
In vitro blocking study
U87 MG cells were seeded into a 96-well plate in a con-
centration of 1 × 104 cells per well. After 24 h, the cells
were incubated with either the fluorescent PARP1 in-
hibitor PARPi-FL (250 nM) alone or with one of the
iodo-PARPi inhibitors at a 100-fold higher concentration
(25 μM) for 20 min. Additionally, as a positive control,
the PARP1 inhibitor Olaparib was used. All incubation
solutions also included Hoechst 33342 nuclear stain
(Sigma-Aldrich, St. Louis, MO). The cells were washed
twice with media and once with PBS for 5 min each and
imaged on an LSM 5Live confocal microscope (Zeiss,
Oberkochen, Germany). All wells were imaged with theDAPI filter for the Hoechst staining and the FITC filter
for the PARPi-FL staining. The DAPI and FITC channels
were co-registered, and the green fluorescence in the
location of the Hoechst staining was quantified for each
image. The percent reduction in PARPi-FL uptake was
calculated based on the level of fluorescence intensity
seen in each image and normalized to the cells receiving
no iodo-PARPi inhibitor. Experiments were performed
in triplicate.
Blood half-life
Blood half-life was determined by measuring the activity
in serial blood samplings. Specifically, healthy female
nude mice (8–10 weeks old, 20–25 g in weight, n = 3)
were injected via the tail vein with 50 μCi [131I]-I2-
PARPi in 200 μL of solution PBS/PEG300 (10:1). The
blood was sampled from the saphenous vein at 5, 15, 30,
60, 120, and 240 min post injection. The blood was
weighed and radioactivity was measured on a Wizard
2470 Automatic Gamma Counter (Perkin Elmer, Waltham,
MA). Measurements in counts per minute were calculated
as the mean %ID/g. The blood half-life was calculated using
Prism 6.0c (GraphPad Software, La Jolla, CA).
In vivo blocking study
To verify the specificity of tumor uptake of I2-PARPi
in vivo, the level of blocking of the fluorescent PARP1
inhibitor on a macroscopic and microscopic scale was
determined. Nude mice bearing subcutaneous U87 MG
tumors were injected with either the fluorescent PARP1
inhibitor PARPi-FL alone (2.5 mg/kg, 200 μL of 19.5 %
1:1 DMAC:Kolliphor, 3.5 % DMSO, 77 % PBS), PARPi-
FL 30 min after a pre-injection of a 50-fold excess of I2-
PARPi (125 mg/kg, 100 μL of 10 % PEG300, 90 % PBS),
or injected with saline alone. One hour post injection,
the mice were sacrificed and the tumors were resected
and imaged with the IVIS spectrum fluorescence im-
aging system (PerkinElmer, Waltham, MA) using Living
Image 4.4 software. The tumors were also imaged micro-
scopically with the 5Live fluorescent confocal micro-
scope using the 488 nm laser for PARPi-FL excitation.
In vitro whole blood stability
The in vitro stability was assessed by incubating 6 μCi
[131I]-PARPi in mouse blood for 0 to 60 min at 37 °C. At
baseline, 15, 30, and 60 min, the samples were immedi-
ately placed on ice and mixed 1:1 with a solution of
AcN/DMSO (250 μL) and then vigorously vortexed for
30 s to precipitate out serum protein. The sample was
centrifuged at 3000 RCF for 3 min at 4 °C, and the
supernatant was collected. This procedure was repeated
three times, and the combined supernatants were ana-
lyzed by HPLC equipped with radioactive detector
(Shimadzu, Kyoto, Japan), collecting samples every 30 s.
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2470 Automatic Gamma Counter (Perkin Elmer, Waltham,
MA), and the blood stability was analyzed using Prism 6.0c
(GraphPad Software, La Jolla, CA).
Biodistribution studies
Biodistribution experiments were conducted on female
nude mice (8–10 weeks old and 20–25 g in weight,
n = 21) bearing U87 MG or U251 MG subcutaneous
xenografts. The radiolabeled small molecule preparation
(30–20 μCi of [131I]-I2-PARPi in 200 μL of a solution
90 % PBS 10 % PEG300) was administrated via the lateral
tail vein. To determine the optimal specific activity to
achieve the highest tumor to organ ratio, various specific
activities were tested (5, 50, and 250 mCi/μmol) in mice
bearing U87 MG tumors. The compound was allowed to
circulate for 2 h post injection at which time the mice
were sacrificed and organs were harvested (n = 3). After
determining the optimal specific activity, the optimal time
for imaging was determined by testing the drug distribu-
tion in nude mice bearing U87 MG tumors at different
time points. The drug was allowed to circulate for various
times (1, 2, and 6 h), after which the mice were sacrificed
(n = 3). The radioactive content in the tissue of interest
(blood, tumor, muscle, bone, liver, spleen, kidney, heart,
lung, pancreas, brain, skin, small intestine, large intestine,
stomach, tail, thyroid, and feces) was measured on a
Wizard 2470 Automatic Gamma Counter and the tissue-
associated activity was calculated as the mean %ID/g.
Autoradiography
U251 MG glioblastoma cells (5 × 104 in 2 μL of PBS)
were orthotopically implanted in athymic nude mice,
using a stereotaxic device, and the tumors were allowed
to grow for approximately 4 weeks. Once tumors
reached the sufficient size, the orthotopic U251 MG
tumor-bearing mice were injected intravenously with
500 μCi [131I]-PARPi (in 200 μL of a solution PBS 90 %
PEG300 10 %, n = 2) alone or with a pre-injection of
15 μmol Olaparib (in 100 μL of 7.5 % DMSO, 12.5 %
PEG300, 80 % PBS) 30 min prior to the injection of
[131I]-PARPi. Additionally, healthy mice were also
injected with 500 μCi [131I]-PARPi. After 2 h of circula-
tion time after the [131I]-PARPi injection, the mice were
sacrificed. Liver, tumor, muscle, and brain tissues were
excised and embedded in O.C.T. compound (Sakura
Finetek, Torrance, CA) and frozen at −20 °C, and a
series of 8 μm frozen sections was cut and mounted on
microscope slides. To determine radiotracer distribution,
digital autoradiography was performed by placing tissue
sections in a film cassette against a phosphor image plate
(BASMS-2325; Fujifilm) for 48 h at −20 °C. Phosphor im-
aging plates were read at a pixel resolution of 25 μm with a
Typhoon 7000IP plate reader (GE Healthcare, Piscataway,NJ). After autoradiographic exposure, the same frozen sec-
tions were then used for immunohistochemical staining.
Areas of brain slides containing tumor tissue were identi-
fied using the H&E staining and then overlaid with the
autoradiographic data. Intensity of tumor areas and non-
tumor areas were then quantified using ImageJ 1.47u.
In vivo imaging
SPECT/CT was acquired in athymic nude mice (6–10
weeks old). Before administration of the radioiodinated
tracer, in terms to block the thyroid, the animals were
treated with an intraperitoneal injection of NaI (100 μL,
0.6 mM) 60 min previous to the injection of 450–
600 μCi (145–210 mCi/μmol) [131I]-I2-PARPi in 200 μL
PBS solution (10 % PEG300) via the lateral tail vein and
then anesthetized with isoflurane mixed with medical air
(2 % for induction and maintenance). Animals were
placed in prone position, and scans were then performed
90 min after injection for 60 min using a SPECT/CT
small animal imaging system (NanoSPECT/CT, Mediso,
Boston, MA). SPECT Images were reconstructed using
HiSPECT software, and in vivo Scope software was used
for CT image reconstruction.
In the case of PET imaging, images were acquired after
the injection of 200–250 μCi (110–170 mCi/μmol)
[124I]-I2-PARPi in 200 μL PBS solution (10 % PEG300)
via the lateral tail vein under isoflurane anesthesia (2 %
for induction and 1.5 % for maintenance). Mice were
also treated with an intraperitoneal injection of NaI
(100 μL, 0.6 mM), 60 min previous to the administration
of the radioiodinated tracer. Animals were immediately
placed in prone position under isoflurane anesthesia,
and scans were then performed 90 min after injection
for 30 min using the Inveon PET/CT imaging system
(Siemens, Knoxville, TN). PET and CT Images were
reconstructed using Inveon research workplace software.
Formulation of [131/124I]-I2-PARPi for in vivo injection
For in vivo applications, the radioactive 124I/131I-I2-
PARPi was injected intravenously, using hypodermic sy-
ringes with 200 μL of a solution of PBS 1× and PEG300
(9/1 v/v). We used approximately 450–600 μCi of radio-
tracer for PET imaging, 200–250 μCi for SPECT im-




Immunofluorescence PARP1 antigen detection in histo-
logical sections of U251 MG and U87 MG glioblastoma
xenografts showed an overexpression of PARP1 com-
pared to healthy brain tissue (Fig. 1a). The PARP1 posi-
tive area in glioblastoma slides was increased by a factor
of 15.8 ± 8.1 (Fig. 1b). The percent PARP1 positive area
Fig. 1 PARP1 immunofluorescence staining of brain, U251 MG xenografts, and U87 MG xenografts. a Representative images showing H&E staining (left)
and PARP1 immunofluorescence staining (right) of each tissue type. b Percent of nuclei positive for PARP1 for each tissue type. c Average intensity of
nuclei in each cell type
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10.4 % and 41.5 ± 11.0 % for U251 MG and U87 MG, re-
spectively (for healthy brain, PARP1 positive area was
2.7 ± 1.3 %). In the same way, glioblastoma tissues
present similar values in average intensity (99.5 ± 8.5 AU
for U251 MG and 106.2 ± 10.5 AU for U87 MG, Fig. 1c)
with values over 14-fold higher than healthy tissue, con-
firming optimal target/background ratios for in vivo
evaluation.
Synthesis of iodinated PARP1 inhibitors
The molecular structure of all iodinated PARP1 tracers
is based on the (2H)-phthalazin-1-one scaffold of the
small molecule therapeutic Olaparib (Fig. 2a). The syn-
thesis of a library of test compounds, consisting of six
different inhibitors (Fig. 2), was carried out through the
coupling of the PARP Inhibitor precursor 4-(4-fluoro-3-
(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one and
different iodinated carboxylic acids. The reaction was
performed in the presence of HBTU and triethyla-
mine or EDC and NHS at room temperature, over-
night, and crude mixtures were purified by HPLC or
silica column, resulting in the isolation of I1-PARPi
through I6-PARPi in good yields (Fig. 2b, Additional
file 1: Figures S2 and S3).Pharmacokinetic properties of non-radioactive
compounds
The obtained IC50 values of all the small molecules were
in the nanomolar range (9 ± 2–107 ± 4 nM). I1-PARPi
and I2-PARPi showed the highest affinity (11 ± 3 and
9 ± 2 nM, respectively), with values close to Olaparib
(5 nM, [22]). All inhibitors had a CHI between 59.6
and 71.6, which corresponds to LogPCHI values between
2.3 and 3.0. These values were lower for Olaparib (CHI =
34.1, LogCHI = 0.8) but adequate for crossing the blood-
brain barrier for application in brain diseases [2]. The
iodinated molecules showed relatively high plasma protein
binding, with the protein plasma free fraction ranging
between 4.69 and 11.53 % (Fig. 3).
In vitro and in vivo competitive optical imaging
To demonstrate the specific binding of our inhibitors to
PARP1, in vitro competition assays were performed with
the small molecules and their fluorescent sister imaging
agent, PARPi-FL [25]. PARPi-FL alone led to strong nu-
clear fluorescence, where the agent was retained by
PARP1. The reduction in fluorescent signal in the pres-
ence of all inhibitors confirmed their ability to diffuse
into the nucleus of the cell and bind PARP1 (Fig. 4a).
When PARPi-FL was added to cells that were co-treated
Fig. 2 Structure of Olaparib and iodo-PARPi inhibitors. a Molecular structure of Olaparib. b General structure of I-PARPi derivatives. c Molecular
structures of I-PARPi derivatives, yields, and synthetic parameters
Fig. 3 Biochemical parameters and binding affinity of iodo-PARPi derivatives. a Percent inhibition of PARP1 using a range of concentrations of
the inhibitors I1–I6. b Table of IC50 values calculated from a, along with the values of chromatographic hydrophobicity index (CHI), LogPCHI, and
plasma free fraction
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Fig. 4 In vitro competitive inhibition of PARPi-FL uptake in U87 MG
cells with the different iodo-PARPi derivatives. a Representative confocal
images of cells stained with PARPi-FL (green) and Hoechst 33342 (blue)
alone (left) or stained with PARPi-FL (250 nM) and Hoechst 33342 after
addition of iodo-PARPi (25 μM) (right). b Effectiveness of the iodo-PARPi
inhibitors to saturate PARP1, measured in % unblocked of each
iodo-PARPi derivative along with the PARP1 inhibitor Olaparib
Salinas et al. EJNMMI Research  (2015) 5:46 Page 9 of 14with any of the iodo-PARPi agents, a reduction in fluor-
escence signal between 76 ± 6 and 67 ± 13 % (Fig. 4b)
was seen. This was similar to results obtained for
Olaparib, where co-treatment resulted in a reduction of
PARPi-FL uptake by 73 ± 10 %.
The binding characteristics of non-radioactive I2-
PARPi were explored ex vivo by epifluorescence imaging
of U87 MG tumor tissue. The tissue was obtained from
mice that were injected with I2-PARPi before receiving
an injection of PARPi-FL. A second group received
PARPi-FL alone, without injection of I2-PARPi (Fig. 5a).
Mice receiving both agents showed a 78 ± 4 % lower
tumor fluorescence, compared with the mice receiving
just PARPi-FL (4.53 × 107 ± 0.81 × 107 and 2.03 × 108 ±
1.84 × 107 average radiant efficiency, respectively). A
control group received just PBS, and tumors from these
mice did not show significant fluorescence (0.42 × 106 ±0.07 × 106 average radiant efficiency). Similar results
could be seen using confocal microscopy (Fig. 5c–e),
where tumors from mice injected with PARPi-FL show
clear nuclear uptake in U87 MG tumors (Fig. 5c),
whereas there was a significant decrease in uptake for
mice which also received I2-PARPi (Fig. 5d), similar to
what was observed for the control tumors (Fig. 5e).
Radiolabeling and stability of [131I]-I2-PARPi
The preparation of the radiotracer [131I]-I2-PARPi was
realized in two synthetic steps. First, the precursor N-
succinimidyl-4-(tributylstannyl) benzoate was labeled in
the presence of [131I]-NaI and chloramine T in acetic
acid (Additional file 1: Figure S4 A) and isolated by
HPLC (Additional file 1: Figure S4 C), with a radiochem-
ical yield of 67 ± 6 % (n = 12). The resulting radioactive
N-succinimidyl-4-(131I-iodo) benzoate was then conju-
gated to a PARP1 targeting 2H-phthalazin-1-one in the
presence of HBTU and AcN at room temperature
(Fig. 6a). The crude mixture was purified by HPLC,
yielding the pure product with a radiochemical yield of
72 ± 8 % (n = 12) and a radiochemical purity >95 %.
HPLC chromatograms and mass spectrometry data are
shown in Fig. 6b–d. For obtaining [124I]-I2-PARPi, an
identical procedure was used, which results in yields of
68 ± 5 % (n = 5) and a radiochemical purity >95 %.
In vitro blood stability studies (37 °C) showed only
one main peak at 15 min, corresponding to the pure
compound [131I]-I2-PARPi. We did not observe other
major peaks, which would indicate small molecule me-
tabolites, which confirmed the stability of the drug over
the course of 120 min (Additional file 1: Figure S5 A–C).
In vivo pharmacokinetics of [131I]-I2-PARPi
We determined the blood half-life of [131I]-I2-PARPi in
healthy athymic nude mice (Additional file 1: Figure S6).
The tracer was quickly cleared from the blood, similar to
other inhibitors of this type [2, 26, 27], with an alpha
blood half-life of 14.3 min (96.25 %) and beta blood half-
life of 94.6 min (3.75 %), resulting in a weighted blood
half-life of t1/2(weighted) = 17.1 min (Additional file 1:
Figure S6). The biodistribution of [131I]-I2-PARPi was
analyzed after administration of the radiolabeled tracer
(24 ± 5 μCi) in U87 MG tumor-bearing mice (Fig. 7a, b).
Administration of [131I]-I2-PARPi with a specific activity
of 50 mCi/μmol showed the best tumor/muscle and
tumor/brain ratios (Fig. 7a, Additional file 1: Table S1),
which is why this specific activity was selected for fur-
ther in vivo imaging experiments. Administration of
[131I]-I2-PARPi with a specific activity of 50 mCi/μmol
showed the best tumor/muscle and tumor/brain ratios
(Fig. 7a, Additional file 1: Table S1). Figure 7b compares
the biodistribution of the radiotracer after different time
points. The most favorable tumor/muscle and tumor/
Fig. 5 In vivo competitive inhibition of PARPi-FL uptake in U87 MG subcutaneous tumors with I2-PARPi. a White light, fluorescent, and overlay
images of whole tumor tissues resected from mice treated with PBS (top), PARPi-FL alone (2.5 mg/kg, 200 μL of 19.5 % 1:1 DMAC:Kolliphor, 3.5 %
DMSO, 77 % PBS) (middle), or PARPi-FL (2.5 mg/kg, 200 μL of 19.5 % 1:1 DMAC:Kolliphor, 3.5 % DMSO, 77 % PBS) and I2-PARPi (125 mg/kg, 100 μL
of 10 % PEG300, 90 % PBS) (bottom). b Fluorescence intensity of tissues shown in a. c–e Microscopic fluorescence images of tissues shown in a
Fig. 6 Radiochemical synthesis of I2-PARPi. a Coupling reaction with para-iodo NHS-benzoate and PARPi precursor. b HPLC chromatogram of
[131I]-I2-PARPi (radiotrace in blue, UV trace in black). c,d Mass spectrometry chromatograms of I2-PARPi
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Fig. 7 Biodistribution of [131I]-I2-PARPi in selected organs. a Comparison of the biodistribution of different specific activities of the compound 2 h
post injection. b Comparison of the biodistribution of the compound at 1, 2, and 4 h post injection. Additional biodistribution data can be found
in Additional file 1: Tables S1 and S2
Salinas et al. EJNMMI Research  (2015) 5:46 Page 11 of 14brain ratios were seen at 2 h post intravenous injection
(0.50 ± 0.08 %ID/g, 0.04 ± 0.02 %ID/g and 0.007 ± 0.002
%ID/g for tumor, muscle, and brain, respectively). Figure 7
shows selected tissues, and a full biodistribution table is
shown in Additional file 1: Table S2.
In vivo imaging and autoradiography
With the aim of determining the potential of radioiodi-
nated I2-PARPi as a glioblastoma imaging agent, small
animal SPECT/CT and PET/CT studies were performed
in athymic nude mice bearing orthotopic U251 MG xe-
nografts. SPECT/CT studies were performed using
[131I]-I2-PARPi, and PET/CT studies were performed
with the structural analog [124I]-I2-PARPi. In SPECT/
CT, acquired 90 min post injection of the [131I]-I2-
PARPi, the orthotopic tumor could be readily visualized,
with uptake of the tracer in the right hemisphere of the
brain, where the tumor was implanted (Fig. 8a). This
data is also supported by ex vivo autoradiography. Histo-
logical sections of orthotopic U251 MG tumors showed
a clear delineation of tumor tissue with [131I]-I2-PARPi,
but not for mice where PARP1 was saturated with a pre-
injection of the non-labeled PARP1 inhibitor Olaparib
(Fig. 8b). The signal intensity of [131I]-I2-PARPi in tumor
tissue of mice that received no Olaparib was 15.7-fold
higher than healthy brain tissue (Fig. 8c) and 6.2-fold
higher than muscle tissue (Fig. 8d), corroborating the
SPECT data. There was a 65 % reduction in the intensity
of the autoradiography signal in tumor tissue for mice
that had been treated with Olaparib (1222 ± 203 and
536 ± 87 AU for mice without and with Olaparib treat-
ment, respectively), further verifying the specificity of
the compound. In contrast, the intensity of the muscle
did not undergo statistically significant changes (192 ±
20 and 248 ± 72 AU for mice without and with Olaparib
treatment, respectively, Fig. 8d).PET/CT data was obtained after intravenous injection
180–230 μCi of [124I]-I2-PARPi (110–170 mCi/μmol).
Similar to SPECT/CT, orthotopic U251 MG xenografts
were clearly visualized non-invasively, whereas healthy
mice showed negligible uptake of the tracer (Fig. 9a). Ex
vivo biodistribution data with [131I]-I2-PARPi corrobo-
rated the PET/CT data (Fig. 9b and Additional file 1:
Table. S3A). Comparably to U87 MG, we determined
the tumor uptake in U251 MG to be 0.43 ± 0.05 %ID/g,
whereas only a minute amount of tracer was retained in
the healthy brain (0.011 ± 0.003 %ID/g). High uptake
was observed in the liver (2.4 ± 0.6 %ID/g), which is
common for intravenously administered small molecules
that are excreted hepatobiliary. The tumor/brain ratio
was found to be 40.0 ± 6.3, and the tumor/muscle ratio
was 13.7 ± 4.1 (Fig. 9c and Additional file 1: Table S3B)
indicating potential clinical value of the tracer.
Discussion and conclusions
Glioblastoma multiforme (GBM) is characterized by ag-
gressive malignant infiltrative growth and is associated
with a dismal prognosis [28]. Current standard of care
for non-invasive glioblastoma diagnosis is MRI [29, 30],
which often offers acceptable information regarding the
size and shape of the tumor. However, this tool is often
unable to characterize the underlying histopathology of
the disease. Better and more accurate tools are therefore
desperately needed, particularly for detecting glioblast-
oma at low levels of infiltration [8]. The first step of this
work was the development of a library of novel, iodin-
ated small molecules, which are targeted to PARP1 via
their 2H-phthalazin-1-one group. Biochemical assays
and basic pharmacokinetic evaluation showed that some
of the small molecules had IC50 values close to 10 nM
(9 ± 2 nM and 11 ± 3 nM for I2-PARPi and I1-PARPi),
which is close to the original Olaparib [22] and lower
Fig. 8 Uptake of [131I]-I2-PARPi in orthotopic U251 MG brain tumors. a SPECT/CT images of a mouse bearing an orthotopic U251 MG brain tumor
(top) and a healthy mouse treated with [131I]-I2-PARPi (bottom). b Autoradiography and H&E stains of ex vivo brain sections from orthotopic U251
MG brain tumor mice. Mice were treated with [131I]-I2-PARPi alone (left) or [131I]-I2-PARPi with a pre-injection of Olaparib (right). Yellow arrows
point towards the tumors. c, d Quantification of [131I]-I2-PARPi uptake in brain or muscle in non-blocked, blocked, and healthy mice
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agents [26, 27]. The small molecule I2-PARPi, derived
from 4-iodobenzoic acid, demonstrated the best in vitro
PARP1 binding and the optimal biophysical properties
for further use in in vivo (IC50 = 9 ± 2 nM, CHI = 59.6,
logPCHI, plasma free fraction = 11.5 ± 0.1 %; Fig. 3b).
These pharmacokinetic properties were complemented
in vitro and in vivo by competition studies of the non-
radiolabeled I2-PARPi and the fluorescent PARPi-FL
[26, 27]. Fluorescence-based in vitro assays confirmed
selective nuclear accumulation of all our compounds in
U87 MG glioblastoma cells (Fig. 5), where uptake of a
fluorescent PARP1 inhibitor was inhibited in the presence
of the iodo-PARP1 agents, leading to a significant reduc-
tion in nuclear fluorescence intensity between 76 ± 6 and
67 ± 13 %. This reduction was comparable to the parent
scaffold Olaparib (73 ± 11 %). Similarly, in vivo injection
of I2-PARPi reduced the uptake of the fluorescent probe
equally well, confirming the ability of the iodinated small
molecule to bind to PARP1, and to target the enzymeinside of cell nuclei. The radiolabeled analog of this in-
hibitor was obtained through nucleophilic substitution of
the (Bu3)Sn labeled cold precursor with
131I or 124I in mild
conditions with a specific activity between 145–210 and
110–170 mCi/μmol for [131I]-I2-PARPi and [124I]-I2-
PARPi, respectively (Fig. 4a). The tracer showed a
weighted blood half-life t1/2 of 17.1 min (Additional file 1:
Figure S6), a typical pharmacokinetic profile for small
molecules, which matches up with values obtained for
other Olaparib derivatives [2, 23]. In vivo biodistribution
studies of [131I]-I2-PARPi in U251 MG subcutaneous
xenograft models (Additional file 1: Table S3) confirmed
rapid clearance from all organs via the liver (2.3 ±
0.6 %ID/g; Fig. 9c). A significant accumulation of the
tracer in glioblastoma tissue (0.43 ± 0.05 %ID/g; Fig. 9c)
compared to other control tissues like brain (0.011 ±
0.003 %ID/g) or muscle (0.033 ± 0.012 %ID/g) was
observed, leading to a signal/noise ratio of 40.05 ± 6.34
(Fig. 9d), ideal for in vivo imaging. The difference in
tumor to brain uptake was also verified by autoradiography,
Fig. 9 PET imaging of orthotopic brain tumors with [124I]-I2-PARPi. a PET/CT coronal images (left) and corresponding PET images (right) of
orthotopic U251 MG brain tumor mice injected with [124I]-I2-PARPi. b PET/CT coronal images (left) and corresponding PET images (right) of a
healthy mouse treated with [124I]-I2-PARPi. c Biodistribution of [131I]-I2-PARPi in a U251 MG xenograft mouse model (mice were sacrificed 2 h after
tracer injection, additional biodistribution data can be found in Additional file 1: Tables S3A and S3B). d Selected tumor to non-target tissues ratios
of [131I]-I2-PARPi. Radioactivity in tissues is expressed as %ID/g
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that in the healthy brain tissue (Fig. 8b). At the same time,
the PARP1 specificity of our tracer was confirmed after
treatment with the PARP1 inhibitor Olaparib (Fig. 8c)
showing a significant drop in signal intensity. The potential
value of I2-PARPi as a tracer for clinical imaging of glio-
blastoma was corroborated in an orthotopic U251 MG
glioblastoma mouse model by both SPECT/CT and PET/
CT imaging (Figs. 8 and 9), where a clear accumulation of
the tracer in the tumor tissue could be observed.
In summary, we have designed, radiolabeled, and
tested a library of iodinated PARP1 inhibitors, based on
the high affinity of PARP1 to the 2H-phthalazin-1-one
scaffold. The high tolerability of PARP1 for small mole-
cules appended to 2H-phthalazin-1-one resulted in a
number of high affinity binders in our small molecule
library, the best representative of which, [124/131I]-I2-
PARPi, was tested as a PET and SPECT tracer. Our data
demonstrates the specific binding of our I2-PARPi tracer
to PARP1 and illustrates the potential of this tracer for
glioblastoma detection.
Additional file
Additional file 1: Supporting information. This file contains supplemental
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